Recent Nobel Prizes in deep learning, structure prediction, microRNA, and mRNA signal that the pharmaceutical industry is entering a new era of innovation, driven by the rapid rise of generative and foundational AI models. This new generation of AI is poised to accelerate drug discovery, uncovering novel targets and therapeutics that would likely not be found otherwise. These advancements have led to the rise of "TechBios,"companies built from the ground up with AI as the driving force, enabling seamless integration and collaboration between biologists, chemists, and AI researchers. By leveraging complex software stacks and diverse databases, TechBios ensure the scalability, reliability and reproducibility necessary for cutting-edge pharmaceutical research. Merely bolting on these fast-developing AI capabilities to existing pharmaceutical organizations is insufficient. Effectively harnessing the power of AI foundation models requires a level of deep integration and true collaboration that cannot be achieved through traditional approaches. Panelists will discuss this new approach as it calls for a unique kind of partnership that brings together the AI capabilities of technology-driven organizations and the domain expertise of pharmaceutical companies.